WO2024257098A1 - Dispositif lunettes photothérapeutique - Google Patents

Dispositif lunettes photothérapeutique Download PDF

Info

Publication number
WO2024257098A1
WO2024257098A1 PCT/IL2024/050579 IL2024050579W WO2024257098A1 WO 2024257098 A1 WO2024257098 A1 WO 2024257098A1 IL 2024050579 W IL2024050579 W IL 2024050579W WO 2024257098 A1 WO2024257098 A1 WO 2024257098A1
Authority
WO
WIPO (PCT)
Prior art keywords
light
plane
illumination
phototherapeutic
eyewear device
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2024/050579
Other languages
English (en)
Inventor
Shlomo Lev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pbm Medical Technologies Ltd
Original Assignee
Pbm Medical Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pbm Medical Technologies Ltd filed Critical Pbm Medical Technologies Ltd
Publication of WO2024257098A1 publication Critical patent/WO2024257098A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0622—Optical stimulation for exciting neural tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0626—Monitoring, verifying, controlling systems and methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
    • A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
    • A61N2005/0645—Applicators worn by the patient
    • A61N2005/0647—Applicators worn by the patient the applicator adapted to be worn on the head
    • A61N2005/0648—Applicators worn by the patient the applicator adapted to be worn on the head the light being directed to the eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0664—Details
    • A61N2005/0665—Reflectors

Definitions

  • the presently disclosed subject matter relates to an eyewear device including a light emitting source configured for photo therapeutic treatments of the eyes.
  • the eye is the sensory organ of the visual system that inserts the visual image through the cornea and the lens in projects it on the retina.
  • the retina includes lightsensitive cells that convert light energy into electrical signals which are transmitted to the brain to decipher the observed image.
  • the retina contains several types of light-sensitive cells, some of which are called rods which are responsible for night vision and are more concentrated in the circumference of the retina.
  • the density of the rods decreases towards the center of the retina to a point called the Blind Spot.
  • the macula At the center of the retina there is an area called the macula, where most of cells called cones are concentrated.
  • cones There are three types of cones each of which respond specifically to three wavelengths of red, green and blue, which are the three primary colors that make up the color image.
  • retinal cells are structurally supported by nerves cells also known as ganglion cells and bipolar cells as well as by layer of vascular blood vessel (choroid) that supports and supplies oxygen and nutrients to the retinal cells.
  • nerves cells also known as ganglion cells and bipolar cells as well as by layer of vascular blood vessel (choroid) that supports and supplies oxygen and nutrients to the retinal cells.
  • ganglion cells also known as ganglion cells and bipolar cells as well as by layer of vascular blood vessel (choroid) that supports and supplies oxygen and nutrients to the retinal cells.
  • choroid vascular blood vessel
  • Every cell has a defined organelle called the mitochondria, whose main function is to create the energy needed for the cell and provide it in the form of molecules called ATP.
  • Mitochondria are found in retinal cells at a large amount relative to other cell types, hence retinal cells regularly consume considerable amounts of energy compared to cells in other organs.
  • Decreased or impaired function of the various types of retinal cells can be directly the result of a defect in the genetic sequence that causes, among other things,
  • RP- Retinitis Pigmentosa a group of hereditary degenerative disorders which include difficulties in night vision, due to damaged rod and cone photoreceptor cells at the retinal region, which can lead to blindness.
  • the causes of decreased vision may be caused by other factors, however eventually the decreased vision turns into damage to the retinal cells. This damage can come in several forms, which ultimately impair mitochondria and their function and eventually bring about the death of the cells.
  • the main diseases are:
  • DME Diabetic macular degeneration
  • the damage to the retinal cells can be a result of an external factor such as exposure or ingestion of various toxins, for example methanol, pesticides and chemical warfare agents.
  • retinal irradiation at certain wavelengths can stimulate the various retinal mitochondria to increase their activity to produce ATP and thus improve their function, stabilize their activity and slow the disease.
  • wavelength in the yellow spectrum in particaulr 590nm, was found to be benefieical in reducing VEGF protein, which are known to stimulate neovascular, which is a key factor in causing wet AMD.
  • this wavelength in case of a dry AMD reduces the productions of neovascular and prevents macular degeneration.
  • a low-energy radiation method is called photobiomodulation (PBM) and is performed in all wavelength ranges, but is mainly performed in the range between yellow 560nm and near infrared (NIR) 1000 nm. It was proven that such radiation lowers the oxidative stress, increases NO (nitric oxide) release, increases ATP production, and decreases VEFG protein productionimproves cell durability.
  • PBM photobiomodulation
  • CcO Cytochrome C Oxidase
  • RECTIFIED SHEET (RULE 91) enzyme contains a large protein complex with four centers of iron and copper atoms. In addition, this enzyme is responsible for regulating oxygen uptake (ROS) and the production of anti- inflammatory substances, such as NO.
  • ROS oxygen uptake
  • the “action spectrum” of the enzyme is most effective around four peaks in the spectrum. One is around 620 nm, the other around 680 nm, the third around 760 nm and the last one is around 820 nm. Since the spectrum action is similar to the "absorption spectrum", it can be said that the irradiation in the peak absorption regions intensifies the phase of electron transfer within the enzyme and thus the irradiation makes the electrons more available and hence increased ATP rate.
  • Photobiomodulation - PBM which is performed with LED or low-level laser therapy (LLLT) diodes, including light source of a low energy laser or a laser diode of different wavelengths, especially in the red and infrared range.
  • LLLT low-level laser therapy
  • This study describes direct irradiation of a red wavelength of 670 nanometers, performed in the morning using a flashlight that emits energy of 8mW/cm2 for 3 minutes once a day. This causes an improvement in visual indices especially on the subject of Color Contrast Sensitivity - CCS observed 20% improvement in subjects of older ages.
  • This publication describes retinal irradiation of light in the infrared range (780 nm), for dry and wet AMD patients.
  • the radiation was performed twice a day, twice a week at an energy of 7.5 mW / cm2 for 40 seconds (0.3 J / cm2).
  • the device includes a housing having an interior; an eyepiece disposed on the housing and configured and arranged for placement of an eye of the patient adjacent the eyepiece; a first light source producing a first light beam having a first therapeutic wavelength and disposed within the housing; a second light source producing a second light beam having a second therapeutic wavelength and disposed within the housing, where the second therapeutic wavelength differs from the first therapeutic wavelength by at least 25 nm.
  • US20180236258A1 teaches ophthalmic phototherapy devices and associated phototherapy methods for promoting healing of damaged or diseased eye tissue.
  • An ophthalmic phototherapy device includes a light emitting mechanism for transmitting light of at least one preselected wavelength to the eye tissue.
  • An ophthalmic phototherapy method includes directing light of at least one wavelength for a selected period of time to a portion of damaged or diseased eye tissue, whereby the light transmitted to the damaged or diseased eye tissue stimulates cellular activity in the eye tissue to promote healing.
  • US 2016/0067087 teaches a wearable ophthalmic phototherapy device and associated treatment methods to expose an eye to selected multi-wavelengths of light to promote the healing of damaged or diseased eye tissue.
  • the device includes a frame having a front piece and two earpieces extending from the front piece; and at least one light source producing a light beam having a therapeutic wavelength and disposed within or on the frame.
  • the devices can include multiple different light sources to produce light with therapeutic wavelengths that differs from each other by at least 25 nm.
  • the front of the glasses are transparent and allow to see what is in front of the eye, while the radiation at different wavelengths comes from the inside of the frame and thus they come from different angles to the cornea.
  • the presently disclosed subject matter intends to overcome and combine the provision of energy in phototherapy treatment with high efficiency.
  • a phototherapeutic eyewear device including a wearable eyewear frame, a triangular light guide having a first plane and a second plane, perpendicular to the first plane, and a hypotenuse plane disposed at an angle with respect to the second plane, the triangular light guide is mounted on the frame such that the second plane is configured to face an eye of a wearer.
  • the phototherapeutic eyewear device further includes at least one light source configured to emit therapeutic illumination towards the first plane, such that the illumination enters inner portion of the triangular light guide; and a light diffusion coating on the hypotenuse plane configured to diffuse the illumination impinging on an inner surface of the hypotenuse plane, the light diffusion coating is further configured to reflect illumination impinging on the inner surface towards the second surface.
  • the angle is configured such that illumination reflected by the light diffusion coating is directed towards eye of a wearer.
  • the phototherapeutic eyewear device can further include a light integrating box disposed between the at least one light source and the first plane, the integrating box is configured to increase illumination spread angle of the illumination and to guide isotropic illumination toward the first plane.
  • the light integrating box can be a rectangular portion made of reflective material integrally formed with the triangular light guide.
  • the light diffusion coating can be semitransparent configured to allow light impinging on an outer surface of the hypotenuse plane to enter inner portion of the triangular light guide.
  • the light diffusion coating can be configured to selectively reflect light within at least one predetermined wavelength region, and wherein the illumination from the light source is within the wavelength region.
  • the at least one source can include a plurality of light sources each of which is configured to emit therapeutic illumination of a predetermined wavelength.
  • the phototherapeutic eyewear device can further include a controller configured to control illumination of the plurality of light sources.
  • the phototherapeutic eye wear device can further include a controller configured to control illumination of the at least one light source, the controller is configured to selectively operate the at least one light source to a predetermined duration, and to control power of the illumination.
  • the method includes providing phototherapeutic eyewear device, the device includes a wearable eyewear frame, a triangular light guide having a first plane and a second plane, perpendicular to the first plane, and a hypotenuse plane disposed at an angle with respect to the second plane, the triangular light guide is mounted on the frame such that the second plane is configured to face an eye of a wearer.
  • the device further includes at least one light source configured to emit therapeutic illumination towards the first plane, such that the illumination enters inner portion of the triangular light guide, and a light diffusion coating on the hypotenuse plane configured to diffuse the illumination impinging on an inner surface of the hypotenuse plane, the light diffusion coating is further configured to reflect illumination impinging on the inner surface towards the second surface.
  • the method includes activating the at least one light source with power and duration in accordance with a required eye therapy.
  • the light diffusion coating can be semitransparent configured to allow light impinging on an outer surface of the hypotenuse plane to enter inner portion of the triangular light guide, and wherein the activating includes determining power of duration in accordance with amount of light impinging on an outer surface of the hypotenuse.
  • the at least one source include a plurality of light sources each of which is configured to emit therapeutic illumination of a predetermined wavelength, and wherein the activation includes determining a light source to be activated in accordance with a therapeutic plan.
  • the plurality of light sources can include a first light source configured to illuminate light radiation in a first spectrum including wavelength of 590 nm, a second light source configured to illuminate light radiation in a second spectrum including wavelength of 670 nm, and a third light source configured to illuminate light radiation in a third spectrum including wavelength of 850 nm, the step of activation includes activating the first and second light sources simultaneously.
  • Fig. 1A is a perspective view of an eyewear device in accordance with an example of the presently disclosed subject matter
  • Fig. IB is a perspective view of an eyewear device in accordance with another example of the presently disclosed subject matter.
  • Fig. 2 is an exploded view of the eyewear device of Fig. IB;
  • Fig. 3A is a perspective view of the optical arrangement of the eyewear device of Figure 1 A, in accordance with an example of the presently disclosed subject matter;
  • Fig. 3B is a side sectional view of the optical arrangement of Fig. 3A;
  • Fig. 4A is a side sectional view of the optical arrangement of Fig 3A configured for allowing ambient view;
  • Fig. 4B is a side sectional view of the optical arrangement of Fig. 4 A, including a correction prism;
  • Fig. 5 is a front view of an eyewear device in accordance with yet another example of the presently disclosed subject matter
  • the eyewear device 10 includes a wearable eyewear frame 18 and an optical arrangement 20, including one or more light sources 24 (shown in Fig. 2) configured to illuminate the eyes of a user with therapeutic illumination.
  • the eyewear device 10 further includes optical apertures 14 configured for allowing vision therethrough.
  • the eyewear device 10 can be utilized for providing phototherapy to the eye of the user, while allowing the user to view through the eyewear device 10. This way, the
  • RECTIFIED SHEET (RULE 91) user can wear the eyewear device 10 for an extended period of time while performing other daily activities, and receiving at the same time the required phototherapeutic treatment.
  • the eyewear device 10 can include a solid front without optical apertures. According to this example, the eyewear device is configured to provide therapeutic illumination without providing the user with view of the surroundings.
  • the eyewear device 10 includes a controller 42, and a power source 44 configured for providing electricity to the light sources 24.
  • the eyewear frame 18 includes a cover 15 and a seat 46 for holding the power source 44, allowing thereby the power source 44 to be replaced.
  • the eyewear frame 18 further includes an actuator 48, for activating the light sources 24.
  • the eyewear device 10 can further include adapting member 35 configured for facilitating mounting the eyewear device 10 over the face of the user.
  • the adapting member can be made of foam or other flexible materials, and can be configured to block ambient light from reaching the eye of the user while the therapeutic illumination is directed to the eyes.
  • the optical arrangement 20 includes a triangular light guide 30 having a first plane 36 and a second plane 38, perpendicular to the first plane 36, and a hypotenuse plane 32 disposed at an angle with respect to the second plane 38.
  • the triangular light guide is mounted on the frame 18 such that the second plane 38 is configured to face the eye 34 of a wearer.
  • the light sources 24, which can include multiple light sources 24a, 24b and 24c, are configured to emit therapeutic illumination towards the first plane 36, such that the illumination enters inner portion of the triangular light guide 30.
  • the optical arrangement 20 further includes a light integrating box 28 disposed between the light source 24 and the first plane 36 of the triangular light guide 30.
  • the integrating box 28 is configured to increase the illumination spread angle of the illumination emitted from the light source 24 and to guide isotropic illumination toward the first plane 36.
  • the light integrating box 28 can be a rectangular portion having an upper surface 22 and a side surface 26 and can be made of reflective material configured to scatter light and to turn light rays isotropic, such that illumination is uniformly distributed in all directions.
  • light from integrating box 28 enters the triangular light guide 30 through the first plane 36, and the light spreads over a wider angle in comparison with the original beam angle of the light source 24.
  • the integrating box 28 can be integrally formed with the triangular light guide 30, precluding thereby any light fraction between the integrating box 28 and the first plane 36 of the triangular light guide 30.
  • the optical arrangement 20 further includes a light diffusion coating 31 on an inner surface of the hypotenuse plane 32.
  • the light diffusion coating 31 is configured to diffuse the illumination impinging on the inner surface of the hypotenuse plane 32.
  • the light diffusion coating 31 is further configured to reflect illumination impinging on the inner surface of the hypotenuse plane 32 towards the second surface 38.
  • the angle between the hypotenuse plane 32 and the second plane 38 is configured such that illumination reflected by the light diffusion coating 31 is directed towards eye 34 of a wearer.
  • the light diffusion coating 31 can be configured to selectively reflect light in the spectrum of the radiation emitted from the light source 24.
  • the light diffusion coating 31 can be configured to selectively reflect light at least one predetermined spectrum, such that the spectrum having the therapeutic properties is evenly diffused and reflected toward the eye 34. This way, the eye is illuminated with isotropic light specifically in the spectrum, which is most efficient for to achieve the therapeutic goals.
  • the spectrum emitted from the light source 24 is selected depending on the treatment required.
  • a preferred wavelength that provides phototherapy benefits to retain cells and especially to cone cells is a wavelength of 670 nm, which is located at the edge of the visible spectrum. In this way, the interference of the phototherapeutic radiation with the vision through the eyewear device 10 is reduced or even completely precluded.
  • the wavelength can be in the infrared spectrum, for example, 850 nm, which is known to have a good impact on the cone cells of the retina.
  • the light source 24 includes a first light source 24a configured to illuminate light radiation in a first spectrum including a wavelength of 590 nm, a second light source 24b configured to illuminate light radiation in a second spectrum including wavelength of 670 nm.
  • the light source 24 can further include a third light source 24c configured to illuminate light radiation in a third spectrum, including a wavelength of 850 nm.
  • the integrating box 28 can be configured for scattering and mixing light from two or more light sources 24a -24c. This way, the light radiation from the light sources 24a-24c is evenly distributed, providing isotropic illumination toward the first plane 36. It would be appreciated that the dimensions of the integrating box 28 are configured in accordance with the degree of required isotropic illumination taking into consideration the spectrum of each light source 24a-24c.
  • the light diffusion coating 31 can also be configured to diffuse light in each of the spectrums of the light sources 24a-24c.
  • the eyewear device 10 can further include an auxiliary diffuser 50 (shown in Fig. 2) provided on an outer surface of the second plane 38.
  • the auxiliary diffuser 50 can be configured to further evenly distribute the light radiation directed to the eye 34.
  • the position of the auxiliary diffuser 50 on the outer surface of the second plane 38 allows diffusing the illumination from the light sources 24a-24c, regardless of the angle at which it reflects from the hypotenuse plane 32.
  • the eyewear device 10 can be configured to allow the user to view his ambient ambience while using the eyewear device 10.
  • the eyewear device 10 further includes optical apertures 14 configured for allowing vision therethrough.
  • the light diffusion coating 31 is semitransparent and is configured to allow light impinging on an outer surface of the hypotenuse plane 32 to enter an inner portion of the triangular light guide 30.
  • the triangular light guide 30 serves as an optical medium through which the user can view his ambience 40.
  • the user can wear the eyewear device 10 for an extended period of time while performing other daily activities, and receive the required phototherapy treatment at the same time.
  • the light radiation can be set to provide pho to therapeutic, which requires long exposure.
  • the light diffusion coating 31 can be metallic coating such as gold, aluminum or silver and the thickness of the coating determines the reflecting rate of the light radiation from the light sources 24a-24c. For example, for coating of 5nm, the light
  • RECTIFIED SHEET (RULE 91) diffusion coating 31 can transmit 50% of the light rays from the outside while reflecting 50% of the light radiation from the light sources 24a- 24c.
  • the power of the therapeutic light can be determined by controlling the power of the light sources 24a- 24c.
  • a correction member 45 can be provided on the outer surface of the hypotenuse plane 32.
  • the correction member 45 can be a triangular prism configured to cancel out the distortion caused by the angle between the hypotenuse plane 32 and the second surface 38.
  • the eyewear device 10 can further include a controller 42 (shown in Fig. 2) for controlling the operation of the light sources 24a-24c, such as controlling the wavelengths of the light, and the duration of the radiation.
  • the controller 42 can be configured to provide the required therapeutic light radiation in accordance with a predetermined treatment protocol.
  • the controller 42 can be configured to automatically initiate the therapeutic protocol.
  • the controller 42 can be configured to initiate the therapeutic illumination at predetermined times of the day, such that the user can continue his daily activities while receiving the therapeutic illumination automatically.
  • the eyewear device 10 can include a transceiver 49 (shown in Fig. 2) allowing sending the controller 42 instructions related to the required treatment protocol, and for controlling the eyewear device 10.
  • the transceiver 49 can be configured for short range communication, such as Bluetooth, and can be configured for communicating with a handheld device, such as a smartphone.
  • the smartphone can be provided with a designated application to control the operation of the eyewear device 10.
  • the application can be coupled to a remote server and can be further configured for communication with a remote controller, thereby allowing remote control of the eyewear device 10, such as via telemedicine services.
  • the eyewear device 60 can be a clip on eyeglasses, including a frame 62 and a pair of optical arrangement 20, similar to those described above.
  • the eyewear device 60 can a clip-on device, and can include a coupling member 44 for coupling to a frame of glasses 100.
  • the coupling device 44 can be configured as a universal coupler, such that the eyewear device 60 can be mounted on any eyeglasses.
  • the optical arrangements 20 are configured to allow vision therethrough and are further configured for illuminating the eye with therapeutic light radiation, such that the user can receive a therapeutic treatment while using the eyewear device 60 for vision.
  • the optical arrangement 20, thus includes a light source 24 configured for emitting therapeutic light radiation for phototherapy of a part of a human visual system.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

L'invention concerne un dispositif lunettes photothérapeutique, le dispositif comprenant un cadre de lunettes portable et un guide de lumière triangulaire. Le guide de lumière triangulaire comprend un premier plan et un second plan, perpendiculaire au premier plan, et un plan d'hypoténuse disposé à un angle par rapport au second plan. Le guide de lumière triangulaire est monté sur le cadre de telle sorte que le second plan est conçu pour faire face à un œil d'un porteur. Le dispositif comprend en outre au moins une source de lumière configurée pour émettre un éclairage thérapeutique vers le premier plan, de telle sorte que l'éclairage entre dans une partie interne du guide de lumière triangulaire. Le dispositif comprend en outre un revêtement de diffusion de lumière sur le plan d'hypoténuse configuré pour diffuser l'éclairage incident sur une surface interne du plan d'hypoténuse, le revêtement de diffusion de lumière étant en outre configuré pour réfléchir l'éclairage incident sur la surface interne vers la seconde surface.
PCT/IL2024/050579 2023-06-14 2024-06-11 Dispositif lunettes photothérapeutique Ceased WO2024257098A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363507994P 2023-06-14 2023-06-14
US63/507,994 2023-06-14

Publications (1)

Publication Number Publication Date
WO2024257098A1 true WO2024257098A1 (fr) 2024-12-19

Family

ID=93851580

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2024/050579 Ceased WO2024257098A1 (fr) 2023-06-14 2024-06-11 Dispositif lunettes photothérapeutique

Country Status (1)

Country Link
WO (1) WO2024257098A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160067087A1 (en) * 2014-09-09 2016-03-10 LumiThera, Inc. Wearable devices and methods for multi-wavelength photobiomodulation for ocular treatments
EP3281056A1 (fr) * 2015-04-10 2018-02-14 Essilor International Dispositif d'affichage monté sur la tête
US20200368487A1 (en) * 2019-05-20 2020-11-26 Quantum Photonics Corporation System and a method for turnkey neurological solution
EP4135835A1 (fr) * 2020-04-15 2023-02-22 Ciromed GmbH Appareil de traitement de la rétine par rayonnement

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160067087A1 (en) * 2014-09-09 2016-03-10 LumiThera, Inc. Wearable devices and methods for multi-wavelength photobiomodulation for ocular treatments
EP3281056A1 (fr) * 2015-04-10 2018-02-14 Essilor International Dispositif d'affichage monté sur la tête
US20200368487A1 (en) * 2019-05-20 2020-11-26 Quantum Photonics Corporation System and a method for turnkey neurological solution
EP4135835A1 (fr) * 2020-04-15 2023-02-22 Ciromed GmbH Appareil de traitement de la rétine par rayonnement

Similar Documents

Publication Publication Date Title
JP6848032B2 (ja) 損傷又は疾患組織の非侵襲的治療のための、多重波長光線療法装置、システム及び方法
US6319273B1 (en) Illuminating device for treating eye disease
US7288106B2 (en) System and method for excitation of photoreactive compounds in eye tissue
US6350275B1 (en) Devices for treating circadian rhythm disorders using LED's
US20150088231A1 (en) Ocular treatment system and method using red and gold phototherapy
US20160067087A1 (en) Wearable devices and methods for multi-wavelength photobiomodulation for ocular treatments
ES3041687T3 (en) Ophthalmic treatment device
CN219398737U (zh) 一种哺光设备
US9044567B2 (en) Phototherapy method and device
WO2019153967A1 (fr) Dispositif d'éclairage pour la régulation coopérative de rythmes biologiques humains dans de multiples trajets
US20230120782A1 (en) Phototherapy and photobiomodulation device
CN114642834A (zh) 一种近视防控的光疗装置
US20240184144A1 (en) Electromagnetic waves modulating filter
KR20140020532A (ko) 광학 진단 및 광 치료를 위한 복합 광원 장치
WO2024257098A1 (fr) Dispositif lunettes photothérapeutique
JP7612607B2 (ja) 光信号を投射するための視覚器具
CN1198545C (zh) 眼科激光治疗装置
US20220080220A1 (en) Ophthalmic illumination device
KR102905844B1 (ko) 광원의 복사 전력에 대한 명령 법칙을 이용한 광유전 디바이스 제어 방법 및 관련 디바이스
CN223183925U (zh) 一种镜片组件及哺光设备
CN223183924U (zh) 一种光路系统及哺光设备
WO2025156506A1 (fr) Système d'éclairage pour la myopie, appareil d'éclairage pour la myopie et procédé de commande associé
KR20090119517A (ko) 광 치료용 시스템

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24822976

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE